Quantcast

Latest Genzyme Stories

2014-03-05 12:27:25

Minerva president Rogerio Vivaldi and board chairman Marc Beer leading strategy to advance pipeline of novel therapies targeting applications in neuropsychiatry. CAMBRIDGE, Mass., March 5, 2014 /PRNewswire/ -- Minerva Neurosciences, Inc., a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced the launch of the new company web site (www.minervaneurosciences.com) following the successful transfer of the Minerva Neurosciences corporate...

2014-02-27 16:25:58

TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM)(alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a...

2014-02-27 08:29:40

MISSISSAUGA, ON, Feb. 27, 2014 /CNW/ - Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM) (alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a dosing and administration schedule of two annual treatment courses. The first...

2014-02-27 08:26:12

TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM)(alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a...

2014-02-12 12:31:06

LONDON, Feb. 12, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Translational Regenerative Medicine: Market Prospects 2014-2024Report DetailsOur new study shows you the commercial potential of regenerative treatmentsWhat does the future hold for regenerative medicine? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.Our study lets you assess regenerative medicine: cell-based...

2014-02-06 08:27:40

PARIS, Feb. 6, 2014 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q4 2013 Change (reported) Change (CER) 2013 Change (reported) Change (CER) Net sales EUR8,457m -0.8% +6.5% EUR32,951m -5.7% -0.5% Business net income(1) EUR1,810m...

2014-02-05 08:29:22

Strategic Business Leader Brings Complementary Product Commercialization and Rare Disease Expertise SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), an innovative biotherapeutics enterprise, announced today that Frederic Chereau has joined aTyr as president and chief operating officer. Mr. Chereau has more than 20 years of experience in bringing new rare disease products to market and has held key leadership positions at Shire and Genzyme. Mr. Chereau's appointment will...

2014-01-13 16:26:10

CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive $7.5 million from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from the recently announced alliance between Genzyme and Alnylam. In addition, Isis has the potential to receive royalties on products and a portion of future milestone payments. This transaction underscores the value of Isis' innovation and the leadership role Isis has played in the field of...

2014-01-09 08:26:53

- Industry Veterans Bring a Wealth of Commercial and Business Development Experience - CAMBRIDGE, Mass., Jan. 9, 2014 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced the appointment of Alicia Secor to the newly created position of Chief Commercial Officer, and the appointment of John L. LaMattina to the Company's Board of Directors. Ms. Secor joins Zafgen as an experienced health...

2014-01-08 12:28:46

SARASOTA, Fla., Jan. 8, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Geoffrey F. Cox, Ph.D., to serve on its board of directors. Dr. Cox, currently an independent consultant to the Biotechnology and Life Sciences Industry and Principal of Beacon Street Advisors, brings to the company significant experience of the biotechnology industry, through a number of positions as a Senior Executive...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related